Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This is a study to determine the efficacy of muromonab-CD3 and cyclosporine as treatment in
patients with giant cell myocarditis (GCM). T lymphocytes appear to be involved in GCM.
Muromonab-CD3 has been shown to reduce the number of lymphocytes and cyclosporine inhibits
lymphocyte activation. This treatment may prolong patient survival until transplantation or
ventricular assist device placement is possible.